# Vasoactive Intestinal Peptide (VIP)

Canonical source: https://retacompare.com/encyclopedia/vip

Activates VPAC1 and VPAC2 receptors. Smooth muscle relaxation, vasodilation, secretion stimulation, immune modulation.

Reference facts

Also known asVIP-28CategoryGastrointestinalMechanism of actionActivates VPAC1 and VPAC2 receptors. Smooth muscle relaxation, vasodilation, secretion stimulation, immune modulation.TargetsVPAC1, VPAC2Indications under research or approvedResearch — sarcoidosis (analog Aviptadil, RLF-100, COVID respiratory failure)Regulatory status (reference entry)Not FDA-approved (analog in research)Half-life~2 minutes (rapidly degraded)SequenceHSDAVFTDNYTRLRKQMAVKKYLNSILNSequence notes28-residue peptide of the secretin/glucagon family.Molecular weight (Da)3326First reported1970
    Primary References

Said & Mutt, Eur J Biochem 1970 (VIP)


    Explore research articles about Vasoactive Intestinal Peptide (VIP)


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- Said & Mutt, Eur J Biochem 1970 (VIP): https://pubmed.ncbi.nlm.nih.gov/5499506/